Abivax Reports €530M Cash Runway Into Q4 2027, Phase 3 UC Trial On Track
Abivax finished 2025 with €530.4 million cash and runway into Q4 2027 following a $700.3 million ADS offering. The DSMB found no safety signals in its Phase 3 ABTECT ulcerative colitis trial, which remains on track for late Q2 topline results, and new C-level hires bolster commercialization efforts.
1. Full Year 2025 Financial Results
Abivax closed 2025 with cash, cash equivalents and short-term investments of €530.4 million, underpinned by a $700.3 million net ADS offering in July 2025 and full debt settlements, funding operations into Q4 2027. R&D spending rose to €177.8 million while G&A expenses increased to €67.7 million reflecting higher personnel costs.
2. Phase 3 ABTECT UC Trial Update
The independent DSMB reviewed 100% of randomized patients in the 44-week double-blind ABTECT Phase 3 maintenance trial for ulcerative colitis, noting no new safety signals and nearly 90% completion rate. Topline results are expected in late Q2 2026, maintaining the study’s timeline.
3. Leadership Appointments
Michael Nesrallah, MBA joined as Chief Commercial Officer, leveraging IBD leadership experience to spearhead market preparations. Additional senior hires in Regulatory Affairs and Research aim to support ongoing obefazimod clinical programs.
4. Outlook and Upcoming Events
Abivax will hold its Annual General Meeting on May 11 2026 and publish Q1 2026 results on May 25 2026. The company’s strong balance sheet and leadership appointments position it for the next phase of growth and potential commercialization.